The present invention provides methods for treating anemia in a subject having kidney failure by administering a compound that inhibits hypoxia-inducible factor (HIF) prolyl hydroxylase.

The present invention provides in certain embodiments methods of inhibiting platelet function or thrombosis, inhibiting pyruvate kinase M2 (PKM2) dimerization, and/or treating a disease associated with thrombosis by administering a composition comprising a dimeric pyruvate kinase M2 (PKM2) inhibitor in a patient in need thereof.

The present invention provides in certain embodiments methods of inhibiting platelet function or thrombosis, inhibiting pyruvate kinase M2 (PKM2) dimerization, and/or treating a disease associated with thrombosis by administering a composition comprising a dimeric pyruvate kinase M2 (PKM2) inhibitor in a patient in need thereof.

The invention relates to injectable compositions for combating liver fluke parasites in mammals, comprising clorsulon as the active agent. The invention also provides for an improved method for eradicating and controlling liver fluke parasite infections in a mammal comprising administering the compositions of the invention to the mammal in need thereof.

The invention relates to injectable compositions for combating liver fluke parasites in mammals, comprising clorsulon as the active agent. The invention also provides for an improved method for eradicating and controlling liver fluke parasite infections in a mammal comprising administering the compositions of the invention to the mammal in need thereof.

The invention relates to injectable compositions for combating liver fluke parasites in mammals, comprising clorsulon as the active agent. The invention also provides for an improved method for eradicating and controlling liver fluke parasite infections in a mammal comprising administering the compositions of the invention to the mammal in need thereof.

An effective therapeutic agent for the M2 channel comprising sulfonylamide or oxabicyclo structures effective for treating amantadine-resistant influenza A infections, and methods of treating amantadine-resistant influenza A infections through administration of the same.

An effective therapeutic agent for the M2 channel comprising sulfonylamide or oxabicyclo structures effective for treating amantadine-resistant influenza A infections, and methods of treating amantadine-resistant influenza A infections through administration of the same.

Disclosed herein is a class of molecules termed remodilins that are effective in treating asthma, pulmonary fibrosis, and associated disorders. The molecules ameliorate asthma and pulmonary fibrosis symptoms by various mechanisms, including inhibiting airway smooth muscle contractile protein accumulation, reducing airway constrictor hyperresponsiveness, inhibiting bronchial fibroblast transformation into myofibroblasts, and/or treating or preventing airway or pulmonary fibrosis.

Disclosed herein is a class of molecules termed remodilins that are effective in treating asthma, pulmonary fibrosis, and associated disorders. The molecules ameliorate asthma and pulmonary fibrosis symptoms by various mechanisms, including inhibiting airway smooth muscle contractile protein accumulation, reducing airway constrictor hyperresponsiveness, inhibiting bronchial fibroblast transformation into myofibroblasts, and/or treating or preventing airway or pulmonary fibrosis.